Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | STS | P08842 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.57 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.57 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.57 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4448787 | 0.98 | PTPN1 (0.71) | PTPN1HPGDSTSRAB9AEPHX1 | |
| SCHEMBL23899043 | 0.91 | NAMPT (0.67) | PTPN1HPGDRAB9AEPHX1GAA | |
| SCHEMBL116361 | 0.91 | NAMPT (0.67) | PTPN1HPGDRAB9AEPHX1GAA | |
| SCHEMBL23898941 | 0.91 | NAMPT (0.67) | PTPN1HPGDRAB9AEPHX1GAA | |
| SCHEMBL125695 | 0.91 | PTPN1 (0.89) | PTPN1HPGDSTSRAB9ALMNA | |
| SCHEMBL28656982 | 0.91 | PTPN1 (0.89) | PTPN1HPGDSTSRAB9ALMNA | |
| SCHEMBL11936021 | 0.87 | PTPN1 (0.57) | PTPN1HPGDSTSRAB9AEPHX1 | |
| SCHEMBL1785803 | 0.86 | PTPN1 (0.74) | PTPN1HPGDSTSRAB9ALMNA | |
| SCHEMBL9851155 | 0.84 | PTPN1 (0.77) | PTPN1HPGDSTSRAB9AEPHX1 | |
| SCHEMBL29057710 | 0.84 | PTPN1 (0.77) | PTPN1HPGDSTSRAB9AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | claimed |
| JP-2011526912-A | — | — | 2011-10-20 | — | — | JP | claimed |
| EP-2291376-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | claimed |
| EP-3749355-B1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE (\"NACK\") AND METHODS FOR USE OF THE SAME | UNIV MIAMI (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-113621175-B | Efficient isotactic polypropylene beta-crystal form nucleating agent and preparation method and application thereof | 中国科学院化学研究所 | 2022-10-18 | — | — | CN | disclosed |
| CN-113621175-A | Efficient isotactic polypropylene beta-crystal form nucleating agent and preparation method and application thereof | 中国科学院化学研究所 | 2021-11-09 | — | — | CN | disclosed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2291376-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | AURKA, AURKC, AURKB | PTPN1 839/4885HPGD 2277/4885STS 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.